Navigation Links
Synta Presents Results for STA-4783 in Metastatic Melanoma Showing,Improvement in Overall Survival

ll die of the disease this year," said Karen Graham, Chairman and President of the William S. Graham Foundation for Melanoma Research, Inc. ("The Billy Foundation"). "The five year survival rate for patients diagnosed with stage IV or metastatic disease can be less than 7 percent. We are very encouraged by the Phase 2b clinical trial results for STA-4783 and look forward to Synta initiating the Phase 3 trial in the coming months for first-line treatment of patients with metastatic melanoma."

Additional Survival Results from the Phase 2b Trial

A total of 81 patients were enrolled in the trial, which compared the effects of treatment with STA-4783 plus paclitaxel (N=53) to treatment with paclitaxel alone (N=28). Patients receiving paclitaxel alone were allowed to cross over to the experimental arm upon evidence of disease progression. Of the 28 patients initially treated with paclitaxel alone, 19 patients crossed over after their disease progressed, while 9 patients did not cross over.

Overall survival rates at one year were as follows:

-- STA-4783 + paclitaxel patients 49%

-- Cross-over STA-4783 + paclitaxel patients 53%

-- Patients who did not receive STA-4783 22%

The one-year survival rate for patients treated with STA-4783 compares favorably with results from the only approved chemotherapy for metastatic melanoma, dacarbazine (DTIC). In four recently published randomized, controlled trials, the one-year survival rates for patients treated with DTIC were 15%, 22%, 27%, and 30%, respectively (2).

The median overall survival times, measured in months from time of initial randomization into the trial, were:

-- STA-4783 + paclitaxel patients 12.0

-- Cross-over STA-4783 + paclitaxel patients 14.3

-- Patients who did not receive STA-4783 5.6

The median overall survival times also compare favorably with results from prior trials. Median overall survival times in the recent randomized, cont
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Synta Pharmaceuticals to Host Conference Call Today
2. Synta Oncology Candidate STA-4783 Clinical Trial Results to Be Presented at the ASCO Annual Meeting
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
6. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
7. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
8. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
9. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
10. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
11. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
Post Your Comments:
(Date:5/1/2015)... 2015  Boston Scientific Corporation (NYSE: BSX ) ... and long-term growth strategies at a meeting with the ... . President and Chief Executive Officer Mike ... has to bring forward meaningful innovation to transform patient ... shareholder value. "We are focused on ...
(Date:5/1/2015)... , May 1, 2015  Misonix, Inc. (NASDAQ: ... that designs, manufactures and markets innovative therapeutic ultrasonic ... debridement, cosmetic surgery, laparoscopic surgery and other surgical ... results for the third quarter fiscal year 2015 ... scheduled a conference call that same day, Thursday, ...
(Date:5/1/2015)... RUTHERFORD, N.J., May 1, 2015 Cambrex Corporation (NYSE: ... March 31, 2015. Highlights , ... and increased 27% excluding foreign currency impact, driven by Innovator ... million from $8.4 million in the first quarter of 2014. ... versus $0.04 in the first quarter last year and Adjusted ...
Breaking Medicine Technology:Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 2Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 3Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 4Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 5Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 6Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 7Misonix, Inc. To Report Third Quarter Fiscal Year 2015 Financial Results On Thursday, May 7, 2015 2Cambrex Reports First Quarter 2015 Financial Results 2Cambrex Reports First Quarter 2015 Financial Results 3Cambrex Reports First Quarter 2015 Financial Results 4Cambrex Reports First Quarter 2015 Financial Results 5Cambrex Reports First Quarter 2015 Financial Results 6Cambrex Reports First Quarter 2015 Financial Results 7Cambrex Reports First Quarter 2015 Financial Results 8Cambrex Reports First Quarter 2015 Financial Results 9Cambrex Reports First Quarter 2015 Financial Results 10Cambrex Reports First Quarter 2015 Financial Results 11
... Neurobiological,Technologies, Inc. (NTI(R)) (Nasdaq: NTII ) reported ... detailed analyses supporting the dosing,regimen in NTI,s two ... stroke. The company also provided information as to ... be successful in treating,ischemic stroke than previous Phase ...
... May 14 The Quigley,Corporation (Nasdaq: QGLY ... its wholly owned subsidiary, Quigley Pharma Inc., which ... of its compound,QR448(a). The compound was administered to ... (IBV). The data from the study indicated,that QR448(a) ...
Cached Medicine Technology:Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference 2Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference 3Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference 4Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization 2Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization 3Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization 4Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization 5
(Date:5/3/2015)... (PRWEB) May 03, 2015 It is not too ... Brain Aneurysm Walk in Memory of Lissa Anne Been in ... organized this great family-friendly event to honor her loving memory. It ... inception. , Just having turned 37, Lissa suffered a ... away on August 24, 2012. This event is designed to serve ...
(Date:5/2/2015)... one of only 30 Illinois companies to be a ... Recognition Program (SHARP) certification, Essentra Specialty Tapes ... of Labor to host this special event. The ... Occupational Safety and Health Administration’s (“OSHA”) Onsite Consultation Program ... exceed all of the necessary regulations and standards, thanks ...
(Date:5/2/2015)... (PRWEB) May 02, 2015 Vancouver fencing company, ... now provide valuable advice to prospective clients related to their ... looking to install railings around their decks and patios. While ... questions that pop up once the person rolls up their ... of installing a railing in finding a gate that matches ...
(Date:5/2/2015)... ProText Kinetic 2 is a set of typography creation ... ProText Kinetic 2 features 40 animation presets that ... . Easily create interactive text videos without having to ... 2. , Using ProText Kinetic is as easy as drag ... in the FCPX timeline. Playback the default animation and ...
(Date:5/2/2015)... (PRWEB) May 02, 2015 We are ... The Delray Recovery Center as one of the Top ... known in the addiction treatment field for their ethics ... to innovate and to continue their educational efforts. The ... workplace environment, never forgetting their purpose – to help ...
Breaking Medicine News(10 mins):Health News:Renowned Brain Aneurysm Foundation to Benefit from Arnold, Missouri’s 3rd Annual Brain Aneurysm Walk in Memory of Lissa Anne Been 2Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 2Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 3Health News:Professional Staff at QS Fencing Company Now Provides Advice on Railings and Gates 2Health News:Pixel Film Studios Announced the Release of Protext Kinetic 2 for FPCX. 2Health News:The Delray Recovery Center Named 2015 Top Workplace 2
... ... care, before moving to the U.S. to practice health care in a free-market economy. In ... he warns America of the fragility of such a system and its threat to real ... (PRWEB) December ...
... , ... CT procedures vary widely and are higher than generally thought, raising concerns about increased risk ... (UCSF) imaging specialists. , ... San Francisco, CA (Vocus) December 14, 2009 -- Radiation doses from common CT procedures vary ...
... Statement of Steve Pasierb, President , NEW ... Monitoring the Future study (MTF) -- the largest survey on teen ... underscores that teens, intentional abuse of prescription (Rx) and over-the-counter (OTC) ... number of young people abusing medicines they obtain from friends and ...
... , , , SANTA ANA, Calif., Dec. 14 ... board of directors has authorized a daily distribution to stockholders of ... the period commencing on Jan. 1, 2010 and ending on Feb. ... days in the calendar year and will be equal to an ...
... , , DENVER, Dec. 14 ... Tenth Circuit, affirmed the federal government,s position that private insurance companies ... , Although other federal courts have held that contracts issued by ... Section 1347, US vs. Frost is the first case ...
... Exercise benefited men whose disease had been treated, hadn,t spread, ... appears to reduce the risk of death in male colon ... January 1986, included 668 men who,d been treated for stage ... not spread (nonmetastatic cancer). Every two years, the men were ...
Cached Medicine News:Health News:Canadian Doctor Warns Against Government-Run, Socialized Medicine and its Threat to Health Care and Freedom in America 2Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 2Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 3Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 4Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 5Health News:Partnership for a Drug-Free America(R) Responds to 2009 Monitoring the Future Study Results 2Health News:Partnership for a Drug-Free America(R) Responds to 2009 Monitoring the Future Study Results 3Health News:Grubb & Ellis Healthcare REIT II Declares Initial Distribution 2Health News:Grubb & Ellis Healthcare REIT II Declares Initial Distribution 3Health News:Insurance Now Subject to Federal Jurisdiction 2Health News:Physical Activity May Prolong Survival After Colon Cancer 2
Measures up to 152 mm in 1 mm increments and 6 inches in 1/32 inch increments. Deeply etched graduations and dull finish....
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Medicine Products: